Atossa Genetics, Inc. (NASDAQ: ATOS) Starts Presentation at LD Micro Main Event
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The company is developing a new drug, endoxifen, which can be applied directly to the breast like a lotion, and developing a new way to deliver therapies, such as “CAR-T” cells, through microcatheters to target the site of the breast cancer. For more information, visit the company’s website at www.atossagenetics.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information,…







